9
Participants
Start Date
June 12, 2014
Primary Completion Date
March 20, 2017
Study Completion Date
March 20, 2017
Darbepoetin Alfa
The first dose of darbepoetin alfa was the same as that administered at the last dosing visit of the active treatment period in Study 20090160. Doses could be increased up to a maximum of 500 μg every two weeks (Q2W).
Research Site, Leuven
Research Site, Liège
Research Site, Charleroi
Research Site, Sint-Niklaas
Lead Sponsor
Amgen
INDUSTRY